Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
Apgar JM, Wilkening RR, Parker DL Jr, Meng D, Wildonger KJ, Sperbeck D, Greenlee ML, Balkovec JM, Flattery AM, Abruzzo GK, Galgoci AM, Giacobbe RA, Gill CJ, Hsu MJ, Liberator P, Misura AS, Motyl M, Nielsen Kahn J, Powles M, Racine F, Dragovic J, Fan W, Kirwan R, Lee S, Liu H, Mamai A, Nelson K, Peel M.
Apgar JM, et al. Among authors: flattery am.
Bioorg Med Chem Lett. 2021 Jan 15;32:127661. doi: 10.1016/j.bmcl.2020.127661. Epub 2020 Nov 4.
Bioorg Med Chem Lett. 2021.
PMID: 33160023